The UCLA Neuro-oncology Program conducts extensive translational and clinical research focused on individualizing treatments to extend and improve the lives of patients with primary brain tumors. The program faculty members often collaborate with other investigators in the UCLA Brain Tumor Center and are part of the brain cancer SPORE.
Basic and Translational Research:
UCLA Brain Tumor Center Research
Additional Information - Neuro-Oncology Program:
Neuro-Oncology Program
The Lai Lab
Neuro-Oncology clinical trials include advanced treatment modalities for brain cancer including targeted therapies, viral therapies, and immunotherapies. Other clinical trials include studies in tumor imaging, quality of care, and neurocognition in collaboration with other researchers at UCLA Health.
For questions on clinical trials, contact:
Emese Filka
Clinical Trial Coordinator
310-794-3521
You may find more information on the following clinical trials offered by our program at ClinicalTrials.gov
| UCLA - IRB Number | Study Agent | Targeted Pathology Diagnosis | Trial Phase |
|---|---|---|---|
|
#14-000514 |
Lapatinib with Surgery |
Recurrent High-Grade Glioma |
Early Phase |
|
#14-000800 |
MLN0128 with Surgery |
Preoperative Recurrent Glioblastoma (GBM) |
Pilot Study |
|
#15-001667 |
ACP-196 |
Recurrent GBM |
Phase 1b/2 |
|
#16-000207 |
Nivolumab vs Temozolomide, with RT |
Newly Diagnosed GBM |
Phase 3 |
|
#16-000365 |
Temozolomide plus Radiation Therapy (RT) Combined with Nivolumab |
Newly Diagnosed GBM |
Phase 2 |
|
#16-000464 |
IL-7 (CYT107) |
High Grade Gliomas |
Pilot Study |
|
#16-000576 |
DNX-2401 with Pembrolizumab |
1st or 2nd Recurrent GBM or Gliosarcoma |
Phase 2 |
|
#16-000649 |
ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide |
Newly Diagnosed GBM |
Phase 2b/3 |
|
#16-001865 |
Pembrolizumab |
Recurrent Malignant Glioma |
Pilot Study |
|
#16-001874 |
Abemaciclib |
Recurrent GBM |
Phase 2 |
|
#17-000338 |
Avelumab with HFRT |
Recurrent GBM transformed from low grade glioma |
Phase 2 |
|
#17-000756 |
PT2385 |
Recurrent GBM |
Phase 2 |
|
#17-000758 |
Anti-LAG-3 or Anti-CD137 in Combination with Anti-PD-1 |
Recurrent GBM |
Phase 1 |
|
#17-000794 |
DSP-7888 with Bevacizumab |
Recurrent GBM |
Phase 2 |
|
#17-000998 |
BGB-290 with Temozolomide and/or RT |
Newly Diagnosed GBM or 1st Recurrent GBM |
Phase 1b/2 |
|
#17-001423 |
AMG596 |
Newly Diagnosed GBM or Recurrent GBM |
Phase 1 |
|
#17-001719 |
AG120 or AG881, with surgery |
Recurrent Grade 2 or 3 Low Grade Glioma |
Phase 1 |
Donate Today Giving: Your gift to the UCLA Neuro-Oncology Program makes a difference.
